LACC1-Associated Juvenile Arthritis: A Patient Guide
At a Glance
LACC1-associated juvenile arthritis is a rare inherited inflammatory disease caused by harmful changes in both copies of the LACC1 gene. Genetic sequencing confirms the diagnosis, and individualized treatment, often including biologic medicines, aims to control inflammation and protect joint function.
LACC1-associated juvenile arthritis is a rare, monogenic autoinflammatory disorder that occurs when a child inherits biallelic pathogenic or likely pathogenic variants in the LACC1 gene. This genetic change disrupts the production of a protein called FAMIN, which normally helps immune cells manage energy and control inflammation. When FAMIN is missing or broken, the immune system’s “first responders” become overactive, causing severe dysregulated inflammation—primarily in the joints—without a clear external cause or infection [1][2].
The condition often reveals itself very early in childhood, appearing as severe joint pain, persistent fevers, or unusual swelling in the arms and legs called lymphedema. Unlike more common forms of childhood arthritis, the inflammation in LACC1-associated disease is frequently aggressive and “erosive,” meaning it can quickly wear down the bone and cartilage within the joints. Because it can mimic other types of systemic or polyarticular arthritis, a definitive diagnosis usually requires genetic sequencing to confirm the specific LACC1 defect [3][4].
Managing this condition requires a “treat-to-target” approach, where the goal is not just to reduce pain but to achieve clinically inactive disease, with laboratory results that are normal or acceptably low for the clinical context. While traditional medications are often the starting point, many children require advanced biologic therapies that target specific inflammatory messengers like IL-1 or IL-6. Because the disease is complex and is reported in some cases to potentially be associated with the digestive tract or other areas, care is best managed by a multidisciplinary team led by a pediatric rheumatologist who understands the unique challenges of autoinflammatory genetics [2][5].
While a diagnosis of a rare genetic disease is a major life event, it also provides helpful information, informing individualized decisions. Moving from a broad diagnosis of “arthritis” to the specific knowledge of a LACC1 defect allows your medical team to tailor care, though there is no universally established LACC1-specific treatment protocol. With diligent monitoring and a specialized support system, the focus remains on protecting your child’s joint function and ensuring they can lead an active, fulfilling life [6][7].
What is Known and What Remains Uncertain
While a genetic diagnosis helps, LACC1-specific evidence is limited.
- What is known: It is a genetic, autoinflammatory disease that often causes early, severe joint damage.
- What remains uncertain: There is no universally established treatment protocol. Much of the management, including biologic use and screening for extra-articular features, is extrapolated from broader JIA/sJIA guidelines or small case reports.
In this guide
6 chapters
Understanding LACC1-Associated Juvenile Arthritis
Learn how LACC1 defects cause rare juvenile arthritis, including early onset, joint damage, limb swelling, inheritance, and why genetic testing matters for care.
Recognizing Symptoms and Emergency Red Flags
Learn to recognize LACC1-associated juvenile arthritis symptoms, flares, lymphedema, and emergency red flags such as possible macrophage activation syndrome.
How LACC1-Associated Arthritis is Diagnosed
Learn how LACC1-associated juvenile arthritis is diagnosed through genetic testing, how to read LACC1 results, and what inheritance means for your family.
Treating LACC1-Associated Arthritis
Learn how LACC1-associated juvenile arthritis is treated, including biologics, steroids, blood tests, vaccines, and treat-to-target goals for inactive disease.
Building Your Care Team
Learn which specialists support children with LACC1-associated juvenile arthritis, how to prepare for visits, and how shared care coordinates treatment.
Living with the Long-Term Outlook
Learn how to support a child with LACC1-associated juvenile arthritis, including joint monitoring, warning signs, growth, rehabilitation, and transition planning.
Common questions in this guide
What causes LACC1-associated juvenile arthritis?
What symptoms can LACC1-associated juvenile arthritis cause?
How is LACC1-associated juvenile arthritis diagnosed?
What treatments are used for LACC1-associated juvenile arthritis?
How will doctors know whether treatment is working?
Which specialists should manage this rare condition?
Should children with LACC1-associated arthritis be checked for problems outside the joints?
Get notified when new evidence is published on juvenile arthritis due to defect in LACC1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (7)
- 1
LACC1 deficiency links juvenile arthritis with autophagy and metabolism in macrophages.
Omarjee O, Mathieu AL, Quiniou G, et al.
The Journal of experimental medicine 2021; (218(3)) doi:10.1084/jem.20201006.
PMID: 33606008 - 2
A novel LACC1 variant c.658G>A (p. Asp220Asn) in familial juvenile arthritis: identification and functional analysis.
Alblooshi H, Mustafa N, Khalam AA, et al.
Human genomics 2025; (19(1)):85.
PMID: 40713900 - 3
New or vanishing frontiers: LACC1-associated juvenile arthritis.
Al-Mayouf SM, Yateem M, Al-Dusery H, et al.
International journal of pediatrics & adolescent medicine 2021; (8(1)):44-47 doi:10.1016/j.ijpam.2020.11.005.
PMID: 33718577 - 4
[Monogenic variants in Laccase domain-containing 1 (LACC1) as the cause of juvenile arthritis].
Knieper AM, von Stuckrad ASL, Minden K, et al.
Zeitschrift fur Rheumatologie 2024; (83(1)):4-14 doi:10.1007/s00393-023-01442-2.
PMID: 37921883 - 5
Pan American League of Associations for Rheumatology treatment recommendations for systemic juvenile idiopathic arthritis.
Franco L, Rodrigues Fonseca A, Barzola ML, et al.
Rheumatology advances in practice 2025; (9(4)):rkaf087 doi:10.1093/rap/rkaf087.
PMID: 41234672 - 6
French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's disease.
Quartier P, Belot A, Breton S, et al.
La Revue de medecine interne 2025; (46(8)):449-481 doi:10.1016/j.revmed.2025.06.001.
PMID: 40544011 - 7
The cultural differences in transition assessment: Evaluation of TRANSITION-Q and STARx scales on Turkish rheumatic patients.
Yiğit RE, Çağlayan Ş, Sözeri B
Archives of rheumatology 2024; (39(2)):255-264 doi:10.46497/ArchRheumatol.2024.10379.
PMID: 38933719
This page is for informational purposes only and does not constitute medical advice. A pediatric rheumatologist and genetics team should interpret your child’s LACC1 results and treatment options.